Archive for the 'Staging' Category
December 2nd, 2008. Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma Using Fluorodeoxyglucose Positron Emission Tomography
The tumor lesion exhibited shrinkage on CT and a decrease in the standardized uptake value (SUV) max after the first course of chemotherapy, but exhibited size enlargement and an increase in SUV max after the second course of chemotherapy. These findings suggest that results of quantification of metabolic response by FDG-PET are related to the objective response as determined by CT in patients with MPM.
Posted in CT or CAT scan, Case Study, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Full Archive, PET Scan, Pleural, Staging, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 5th, 2008. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer
Conclusion: In conclusion, SMRP add limited information to the diagnosis of MPM. Nevertheless, SMRP might be a useful measure in treatment and monitoring of MPM. The prognostic impact of SMRP in MPM is not conclusive and needs further evaluation.
October 3rd, 2008. Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
Conclusions: EUS-FNA is feasible and sensitive for MLN staging in patients with MPM who are candidate for multimodality treatment. These data warrant further evaluation.
September 23rd, 2008. Pleural fluid findings as prognostic factors for malignant pleural mesothelioma
However, none of these variables emerged as statistically significant from the multivariate Cox model. In conclusion, our results showed that there is an inverse correlation between the intensity of inflammation and survival.
September 23rd, 2008. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system
Conclusion: This study confirms a preferential pattern of drainage of malignant pleural mesothelioma to N2 rather than N1 lymph nodes, but suggests that N1 only nodal involvement should be classified as lower stage disease. Multiple N2 nodal site involvement could potentially be classified as higher stage disease than single station N2. Our results emphasize the need for larger, confirmatory multicenter studies that could lead to revision of the current staging system.
Posted in Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 19th, 2008. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy
Conclusions: Non-curative surgery is avoided in 29% out of 42 MPM patients by preoperative PET/CT and in further 14% by mediastinoscopy. Even though both procedures are valuable, there are false negative findings with both, urging for even more accurate staging procedures.
September 6th, 2008. Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma
Discussion: The present study shows the efficacy and safety of local radiotherapy in preventing malignant seeding after thoracoscopy in patients with pleural mesothelioma although larger prospective trials are probably still needed to validate this treatment approach.
September 5th, 2008. Systemic Treatments for Mesothelioma: Standard and Novel
These include drugs targeted against the epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, src kinase, histone deacetylase, the proteasome, and mesothelin. Given the progress made in recent years, there is reason to believe that more effective treatments will continue to be developed.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, EGFR, Full Archive, Gemcitabine (Gemzar), General, Irinotecan, Kinase Inhibitors, New & Novel, Pemetrexed (Alimta), Raltitrexed (Tomudex), Staging, Treatment, Type of Assessment:, Vinorelbine | No Comments »
September 2nd, 2008. Diagnosis, Staging, and Surgical Treatment of Malignant Pleural Mesothelioma
The primary goal of surgery in this setting is the resection of all gross disease. The choice of operation, extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), depends on disease stage, pulmonary function, philosophy of the treating physician, and type of planned adjuvant therapy.
Posted in Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Staging, Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 9th, 2008. Malignant mesothelioma: current status and perspective in Japan and the world
In this context, combination therapy with surgery plus chemotherapy and/or radiotherapy is currently considered the standard treatment for patients with respectable MPM. A national survey of EPP was conducted recently in Japan, and a few multicenter clinical trials will start soon.
Posted in Chemotherapy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Radiation, Staging, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma:, thoracoscopy | No Comments »
June 26th, 2008. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
Conclusion: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, melphalan, paclitaxel | No Comments »
June 5th, 2008. Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine
Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.
Posted in Case Study, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Epithelioid, Full Archive, Gemcitabine (Gemzar), Pleural, Pleural Biopsy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, Type of Mesothelioma:, Vinorelbine, thoracoscopy | No Comments »
May 3rd, 2008. Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma
Conclusions: The benefits of this approach include reduction in postoperative pain, risk of biopsy site tumour seeding, and preoperative delay to radical surgery. VACT is feasible in right-sided mesothelioma but has not yet been validated on the left.
April 30th, 2008. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma
Conclusions: In malignant pleural mesothelioma, the presence of occult disease in resection margins and lymph nodes can be identified by immunohistochemistry and significantly influences the prognosis. Cervical mediastinoscopy is useful in all patients considered for radical resection, but all specimens should be processed with immunohistochemical staining.
Posted in Biphasic or Mixed, Determining Efficacy, Diagnosis & Differentiation, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Immunohistochemistry or IHC, Pleural, Sarcomatoid, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 30th, 2008. VATS in Diagnostic and Treatment of Malignant Pleural Mesothelioma on the Occasion of Advanced Pleural Mesothelioma
Conclusion: 1.Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects. 2. Surgical methods improve patient's condition, even in inoperable cases. 3. VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
Posted in CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, General, Pleural, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 9th, 2008. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma
Our study showed that P16 inactivation by homozygous deletions or methylation is a frequent event in Japanese patients with MPMs, relating to poor prognosis. Homozygous deletion is the major cause of P16 inactivation, but methylation also lead to the inactivation of P16 when the P16 alleles are retained.
March 29th, 2008. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
0). Modified RECIST criteria especially in combination with high-resolution MRI is a very accurate and reproducible technique to correctly evaluate early therapy response in MPM.
Posted in CT or CAT scan, Chemotherapy, Diagnosis & Differentiation, Full Archive, MRI, Pleural, RECIST, Staging, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 19th, 2008. F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case report
The use of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography whole body scan has been recently advocated to improve staging and to monitor treatment in pleural mesothelioma. This is the first case describing the use of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the diagnostic work-up of a primary pericardial mesothelioma.
|
|  |
